122 related articles for article (PubMed ID: 19067321)
1. Lipido-sterolic extract of Serenoa repens (LSESr, Permixon) treatment affects human prostate cancer cell membrane organization.
Petrangeli E; Lenti L; Buchetti B; Chinzari P; Sale P; Salvatori L; Ravenna L; Lococo E; Morgante E; Russo A; Frati L; Di Silverio F; Russo MA
J Cell Physiol; 2009 Apr; 219(1):69-76. PubMed ID: 19067321
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan) on human carcinoma cell lines.
Hostanska K; Suter A; Melzer J; Saller R
Anticancer Res; 2007; 27(2):873-81. PubMed ID: 17465214
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia.
Vacherot F; Azzouz M; Gil-Diez-De-Medina S; Colombel M; De La Taille A; Lefrère Belda MA; Abbou CC; Raynaud JP; Chopin DK
Prostate; 2000 Nov; 45(3):259-66. PubMed ID: 11074529
[TBL] [Abstract][Full Text] [Related]
4. Serenoa repens extract targets mitochondria and activates the intrinsic apoptotic pathway in human prostate cancer cells.
Baron A; Mancini M; Caldwell E; Cabrelle A; Bernardi P; Pagano F
BJU Int; 2009 May; 103(9):1275-83. PubMed ID: 19154468
[TBL] [Abstract][Full Text] [Related]
5. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro.
Latil A; Libon C; Templier M; Junquero D; Lantoine-Adam F; Nguyen T
BJU Int; 2012 Sep; 110(6 Pt B):E301-7. PubMed ID: 22520557
[TBL] [Abstract][Full Text] [Related]
6. Effect of permixon on human prostate cell growth: lack of apoptotic action.
Hill B; Kyprianou N
Prostate; 2004 Sep; 61(1):73-80. PubMed ID: 15287095
[TBL] [Abstract][Full Text] [Related]
7. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies.
Paubert-Braquet M; Cousse H; Raynaud JP; Mencia-Huerta JM; Braquet P
Eur Urol; 1998; 33(3):340-7. PubMed ID: 9555564
[TBL] [Abstract][Full Text] [Related]
8. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells.
Lee DH; Szczepanski MJ; Lee YJ
J Cell Biochem; 2009 Apr; 106(6):1113-22. PubMed ID: 19229860
[TBL] [Abstract][Full Text] [Related]
9. The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation.
Siddiqui EJ; Shabbir M; Mikhailidis DP; Thompson CS; Mumtaz FH
J Urol; 2006 Oct; 176(4 Pt 1):1648-53. PubMed ID: 16952708
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia.
Bernichtein S; Pigat N; Camparo P; Latil A; Viltard M; Friedlander G; Goffin V
Prostate; 2015 May; 75(7):706-22. PubMed ID: 25683150
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of cholesterol and phytosterols on cell proliferation, apoptosis and expression of a prostate specific gene in prostate cancer cell lines.
Ifere GO; Barr E; Equan A; Gordon K; Singh UP; Chaudhary J; Igietseme JU; Ananaba GA
Cancer Detect Prev; 2009; 32(4):319-28. PubMed ID: 19186008
[TBL] [Abstract][Full Text] [Related]
12. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate.
Bayne CW; Ross M; Donnelly F; Habib FK
J Urol; 2000 Sep; 164(3 Pt 1):876-81. PubMed ID: 10953171
[TBL] [Abstract][Full Text] [Related]
13. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
Di Silverio F; Monti S; Sciarra A; Varasano PA; Martini C; Lanzara S; D'Eramo G; Di Nicola S; Toscano V
Prostate; 1998 Oct; 37(2):77-83. PubMed ID: 9759701
[TBL] [Abstract][Full Text] [Related]
14. Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.
Wang P; Ma Q; Luo J; Liu B; Tan F; Zhang Z; Chen Z
Cancer Invest; 2009 May; 27(4):369-75. PubMed ID: 19266349
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon.
Raynaud JP; Cousse H; Martin PM
J Steroid Biochem Mol Biol; 2002 Oct; 82(2-3):233-9. PubMed ID: 12477490
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol sensitivity of endogenous and myristoylated Akt.
Adam RM; Mukhopadhyay NK; Kim J; Di Vizio D; Cinar B; Boucher K; Solomon KR; Freeman MR
Cancer Res; 2007 Jul; 67(13):6238-46. PubMed ID: 17616681
[TBL] [Abstract][Full Text] [Related]
17. Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract of Serenoa repens (Permixon) supplemented with [1-14C]-lauric acid, [1-14C]-oleic acid or [4-14C]-beta-sitosterol.
Chevalier G; Benard P; Cousse H; Bengone T
Eur J Drug Metab Pharmacokinet; 1997; 22(1):73-83. PubMed ID: 9179563
[TBL] [Abstract][Full Text] [Related]
18. Androgen-independent effects of Serenoa repens extract (Prostasan®) on prostatic epithelial cell proliferation and inflammation.
Iglesias-Gato D; Carsten T; Vesterlund M; Pousette A; Schoop R; Norstedt G
Phytother Res; 2012 Feb; 26(2):259-64. PubMed ID: 21656602
[TBL] [Abstract][Full Text] [Related]
19. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.
Habib FK; Ross M; Ho CK; Lyons V; Chapman K
Int J Cancer; 2005 Mar; 114(2):190-4. PubMed ID: 15543614
[TBL] [Abstract][Full Text] [Related]
20. Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells.
Minelli A; Bellezza I; Tucci A; Rambotti MG; Conte C; Culig Z
Prostate; 2009 Apr; 69(5):538-47. PubMed ID: 19107848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
